HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Estee Lauder v. Estee

This article was originally published in The Rose Sheet

Executive Summary

Estee Lauder v. Estee: Consent judgment issued Feb. 29 in the U.S. District Court for the Southern District of New York enjoins Huntington Beach, Calif.-based Estee mail order firm from infringing Lauder's Estee mark. The suit, filed Jan. 26, asked that Estee be prohibited from using the Estee mark; cancel its Internet domain name; provide Lauder "any and all products bearing" the Estee name for destruction; supply Lauder with a list of products previously sold and "pay over to [Lauder] all profits realized" by Estee. Lauder also requested punitive damages of $250,000. Estee has agreed to cease production of its products and indicated it will not market the line under a different name...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel